Professor of Ophthalmology, Johns Hopkins University School of Medicine; George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience
Ophthalmology
Dr. Peter A. Campochiaro, MD
|
|
Give Review
Peter A. Campochiaro, MD practices Ophthalmology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He received 17 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Super Doctor", "Achievement Award for Retinal Research", "Senior Research Achievement Award", "Research to Prevent Blindness Senior Scientist Award", "Merit Award", "The George S. and Dolores Dor Eccles Endowed Professorship", "Lew L. Wasserman Merit Award from Research to Prevent Blindness", "Rosenthal Award", "Alcon Research Institute Recognition Award", "Sandoz Research Award", "Henry Strong Denison Research Award", "AOA" and "Phi Beta Kappa". Peter Campochiaro is a published doctor and has 100 publications published. The lastest was: 'Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.' Peter Campochiaro accepts Medicare payments and is registered with Medicare.gov.
Publications
- Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.
- Molecular pathogenesis of retinal and Choroidal vascular diseases.
- Pro-permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; The Ozurdex for Retinal Vein Occlusion (ORVO) Study.
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
- Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).
- Is There Excess Oxidative Stress and Damage in Eyes of Patients with Retinitis Pigmentosa?
- Regression of choroidal neovascularization results in Macular atrophy in anti-vascular endothelial growth factor-treated eyes.
- Monthly Versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion: The SHORE Study.
- Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2.
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study.
- Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema.
- Sustained Delivery Fluocinolone Acetonide Vitreous Implants: Long-Term Benefit in Patients with Chronic Diabetic Macular Edema.
- Neutralization of Vascular Endothelial Growth Factor Slows Progression of Retinal Nonperfusion in Patients with Diabetic Macular Edema.
- RE: Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials.
- Interleukin-18 has Antipermeablity and Antiangiogenic Activities in the Eye; Reciprocal Suppression with VEGF.
- Lysosomal-mediated waste clearance in Retinal pigment epithelial cells is regulated by CRYBA1/βA3/A1-crystallin via V-ATPase-MTORC1 signaling.
- Factors affecting visual outcomes in patients with diabetic Macular edema treated with ranibizumab.
- Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study.
- Long-term Outcomes in Ranibizumab-Treated Patients With Retinal Vein Occlusion; The Role of Progression of Retinal Nonperfusion.
- Long-term suppression of ocular Neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.
- Seven new loci associated with age-related Macular degeneration.
- Ranibizumab for Edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
- Predictive value in Retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
- Suppression of GLUT1; a new strategy to prevent Diabetic complications.
- Vascular disrupting agent for neovascular age related Macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate.
- Ocular Neovascularization.
- Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
- Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study.
- Vascular Endothelial Growth Factor Promotes Progressive Retinal Nonperfusion in Patients with Retinal Vein Occlusion.
- Topical Pazopanib Blocks VEGF-Induced Vascular Leakage and Neovascularization in the Mouse Retina but Is Ineffective in the Rabbit.
- Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
- Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema.
- Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress.
- Overexpression of SOD in retina: Need for increase in H(2)O(2)-detoxifying enzyme in same cellular compartment.
- N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa.
- Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study.
- Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study.
- Gene transfer for neovascular age-related Macular degeneration.
- Antagonism of vascular endothelial growth factor for Macular edema caused by retinal vein occlusions: two-year outcomes.
- N-acetylcysteine promotes long term survival of cones in a model of retinitis pigmentosa.
- Agents that bind annexin A2 suppress ocular Neovascularization.
- Ophthalmic drug delivery systems for the treatment of Retinal diseases: basic research to clinical applications.
- Prolonged blockade of VEGF receptors does not damage Retinal photoreceptors or ganglion cells.
- Digoxin inhibits Retinal ischemia-induced HIF-1alpha expression and ocular neovascularization.
- Topical mecamylamine for diabetic Macular edema.
- The complexity of animal model generation for complex diseases.
- Monitoring ocular drug therapy by analysis of aqueous samples.
- A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related Macular degeneration.
- Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human Vascular endothelial growth factor.
- Oxidative stress promotes ocular Neovascularization.
- ADAM9 is involved in pathological Retinal neovascularization.
- Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa.
- Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage.
- Suppression and regression of Choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.
- An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of Vascular endothelial growth factor Trap-Eye in patients with dia...
- Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and Choroidal neovascularization.
- Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits Choroida...
- EIAV vector-mediated co-delivery of Endostatin and Angiostatin driven by the RPE-specific VMD2 Promoter Inhibits Choroidal Neovascularization.
- Prolonged blockade of VEGF family members does not cause identifiable damage to Retinal neurons or vessels.
- Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa.
- An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular Neovascularization.
- Topical administration of a multi-targeted kinase inhibitor suppresses Choroidal neovascularization and retinal edema.
- MicroRNAs regulate ocular Neovascularization.
- Ranibizumab for Macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.
- Mecamylamine suppresses Basal and nicotine-stimulated Choroidal neovascularization.
- Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related Macular degeneration.
- Trans-scleral delivery of antiangiogenic proteins.
- Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa.
- Seeing the light: new insights into the molecular pathogenesis of Retinal diseases.
- Vegf or EphA2 antisense polyamide-nucleic acids; vascular localization and suppression of Retinal neovascularization.
- Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system.
- Optical coherence tomography findings in persistent diabetic Macular edema: the vitreoMacular interface.
- The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular Neovascularization.
- In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels.
- Oxidative stress modulates complement factor H expression in Retinal pigmented epithelial cells by acetylation of FOXO3.
- Ocular gene transfer with self-complementary AAV vectors.
- Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreoMacular traction.
- Protein transport to Choroid and retina following periocular injection: theoretical and experimental study.
- Molecular targets for Retinal vascular diseases.
- VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family.
- Differential sensitivity of cones to iron-mediated oxidative damage.
- Reduction of p66Shc suppresses oxidative damage in Retinal pigmented epithelial cells and retina.
- Vascular endothelial growth factor is a critical stimulus for diabetic Macular edema.
- Dynamic and quantitative analysis of Choroidal neovascularization by fluorescein angiography.
- Delivery from episcleral exoplants.
- Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.
- Superoxide dismutase 1 protects Retinal cells from oxidative damage.
- Antioxidants reduce cone cell death in a model of retinitis pigmentosa.
- Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of Choroidal neovascularization by inducing apoptosis.
- Suppression and regression of Choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist.
- Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies.
- The iron carrier transferrin is upregulated in retinas from patients with age-related Macular degeneration.
- Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and Retinal neovascularization.
- Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and Choroidal neovascularization, but not retinal vascular development.
- Retinal Degeneration from oxidative damage.
- Ocular versus extraocular Neovascularization: mirror images or vague resemblances.
- Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related Macular degeneration: results of a phase I clinical trial.
- Effects of different types of oxidative stress in RPE cells.
- The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreoMacular traction.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins
University Of Virginia
Procedures Preformed
- Cataract Removal Surgery
- Coreoplasty
- Cornea Transplant
- Glaucoma Surgery
- View All
Conditions Treated
- Age-Related Macular Degeneration
- Aphakia and Other Disorders of Lens
- Astigmatism
- Benign Neoplasm of Choroid
- View All
Doctors Specialties
- Ophthalmology
Accepted Insurances
- Blue Card PPO
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Choice Care PPO
- Kaiser Permanente
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Super Doctor
- Achievement Award for Retinal Research
- Senior Research Achievement Award
- Research to Prevent Blindness Senior Scientist Award
- Merit Award
- The George S. and Dolores Doré Eccles Endowed Professorship
- Lew L. Wasserman Merit Award from Research to Prevent Blindness
- Rosenthal Award
- Alcon Research Institute Recognition Award
- Sandoz Research Award
- Henry Strong Denison Research Award
- AOA
- Phi Beta Kappa
Education
-
University of Virginia -
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Howard County General Hospital -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1598723850 | |
| NPPES Provider LastName | CAMPOCHIARO | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Ophthalmology | |
| Total Claim Count | 131.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598723850 |
| Last Name Of The Provider | CAMPOCHIARO |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Nicholas J. Butler, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hee-Jung Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfred Kronthal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard A. Adler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela K. Mathews, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James W. Karesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander V. On, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Tso, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Connie M. McRill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James K. Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Wexler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joselito S. Navaleza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Farhan I. Merali, MD |
|
|
Dr. Roxana Y. Rivera-Michlig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Celia S. Chen, MD |
|
|
Dr. Derek S. Welsbie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Katherine M. Chen |
|
|
Dr. Ethan H. Tittler, MD |